Hyphens Pharma completes second tranche of Ardence Pharma acquisition

Hyphens Pharma acquired an additional 17% stake.

Hyphens Pharma International completed the second tranche of acquiring 17% of shares in Ardence Pharma on 9 May.

The total consideration for the Tranche 2 Sale Shares, subject at the exchange rate of $1.00: RM3.25 was equivalent to $3.35m (RM10.9m).

Following the transaction, Hyphens Pharma now holds an 82% stake in Ardence Pharma.

The company will make further announcements as and when there are material developments on the proposed acquisition in due course.

Follow the link for more news on

mergers and acquisitions

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia